{"generic":"Technetium Tc 99m Tilmanocept","drugs":["Lymphoseek","Technetium Tc 99m Tilmanocept"],"mono":{"0":{"id":"jxxps0","title":"Generic Names","mono":"Technetium Tc 99m Tilmanocept"},"1":{"id":"jxxps1","title":"Dosing and Indications","sub":{"0":{"id":"jxxps1b4","title":"Adult Dosing","mono":"<ul><li><b>Procedure on lymphatic system, Lymphatic mapping to locate lymph nodes draining primary tumor:<\/b> 18.5 megabecquerels (0.5 millicuries; 50 mcg as a mass dose) INTRADERMAL, SUBQ, SUBAREOLAR, or PERITUMORAL INJECTION at least 15 minutes (MAX, 15 hours) prior to intraoperative lymphatic mapping; concomitant use of local anesthetics is not recommended<\/li><li><b>Sentinel lymph node biopsy, In patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer, or melanoma:<\/b> 18.5 megabecquerels (0.5 millicuries; 50 mcg as a mass dose) INTRADERMAL, SUBQ, SUBAREOLAR, or PERITUMORAL INJECTION at least 15 minutes (MAX, 15 hours) prior to biopsy; concomitant use of local anesthetics is not recommended <\/li><\/ul>"},"1":{"id":"jxxps1b5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"jxxps1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Procedure on lymphatic system, Lymphatic mapping to locate lymph nodes draining primary tumor<\/li><li>Sentinel lymph node biopsy, In patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer, or melanoma<\/li><\/ul>"}}},"3":{"id":"jxxps3","title":"Contraindications\/Warnings","sub":[{"id":"jxxps3b9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"jxxps3b10","title":"Precautions","mono":"<ul><li>hypersensitivity, prior, to dextran or modified forms of dextran (eg, iron dextran); increased risk of hypersensitivity due to chemical similarity<\/li><li>radiopharmaceutical; maintain adequate shielding and handle with care to reduce radiation exposure to personnel and patient<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jxxps3b11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"jxxps3b12","title":"Breast Feeding","mono":"<ul><li>AAP: Radioactive compounds that require temporary cessation of breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"5":{"id":"jxxps5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Injection site irritation (0.7%)<br\/>"},"6":{"id":"jxxps6","title":"Drug Name Info","sub":{"0":{"id":"jxxps6b17","title":"US Trade Names","mono":"Lymphoseek<br\/>"},"2":{"id":"jxxps6b19","title":"Class","mono":"Diagnostic Agent, Radiopharmaceutical Imaging<br\/>"},"3":{"id":"jxxps6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jxxps6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jxxps7","title":"Mechanism Of Action","mono":"Technetium Tc 99m tilmanocept is a radioactive diagnostic agent that accumulates in lymphatic tissue and selectively binds to mannose binding receptor (CD206) located on the surface of macrophages and dendritic cells, allowing diagnostic mapping of lymphatic drainage from primary breast cancer and melanoma tumors.<br\/>"},"8":{"id":"jxxps8","title":"Pharmacokinetics","sub":{"3":{"id":"jxxps8b26","title":"Excretion","mono":"Total body clearance: 0.222 to 0.396\/hour <br\/>"},"4":{"id":"jxxps8b27","title":"Elimination Half Life","mono":"1.75 to 3.05 hours <br\/>"}}},"9":{"id":"jxxps9","title":"Administration","mono":"<b>Injection<\/b><br\/><ul><li>tilmanocept is not for direct administration; proper radiolabeling preparation is required<\/li><li>use waterproof gloves, effective radiation shielding, and appropriate safety measures<\/li><li>determine number of injections prior to product preparation; prepare a separate syringe for each injection<\/li><li>use technetium Tc 99m pertechnetate sodium injection from a technetium Tc 99m generator within 8 hours of elution for radiolabeling<\/li><li>with a sterile syringe, draw 92.5 megabecquerels (2.5 millicuries) technetium Tc 99m pertechnetate sodium injection solution into either about 0.35 mL (for 0.5 mL reconstituted vial volume) or 0.7 mL (for 2.5 mL or 5 mL reconstituted vial volume); assay for technetium Tc 99m activity in a dose calibrator; label and shield vial<\/li><li>add required volume of technetium Tc 99m pertechnetate, sodium injection solution to tilmanocept vial; shake gently; let stand at room temperature for 15 minutes<\/li><li>add supplied diluent to radiolabeled product in vial to bring to reconstituted vial volume of 0.5 mL, 2.5 mL, or 5 mL; assay for total radioactivity; label and shield<\/li><li>determine radiochemical purity; do not use if purity is less than 90%<\/li><li>withdraw required volume into syringes; assay syringes in a dose calibrator; label and shield at room temperature; use within 6 hours of its preparation<\/li><li>give at least 15 minutes but not more than 15 hours prior to lymphatic mapping or sentinel node biopsy<\/li><li>avoid injection into biopsy wound areas<\/li><\/ul>"},"10":{"id":"jxxps10","title":"Monitoring","mono":"<ul><li>localization of lymph nodes indicates efficacy<\/li><li>pregnancy test; within 48 hours prior to administration in women of childbearing potential<\/li><\/ul>"},"11":{"id":"jxxps11","title":"How Supplied","mono":"<b>Lymphoseek<\/b><br\/>Injection Powder for Solution: 250 MCG<br\/>"},"13":{"id":"jxxps13","title":"Clinical Teaching","mono":"<ul><li>Tell nursing women to express and discard milk for at least 60 hours following administration.<\/li><li>Side effects may include injection site pain and irritation.<\/li><\/ul>"}}}